Discover why MDGL's Rezdiffra leads in MASH therapy with rapid US and EU expansion. Learn about growth potential and risks.

Fintel reports that on September 29, 2025, B. Riley Securities maintained coverage of Madrigal Pharmaceuticals (NasdaqGS:MDGL ...

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.

B. Riley raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $560 from $460 and keeps a Buy rating on the shares following a ...

In recent weeks Novo Nordisk has secured several key label expansions for some of its products, which should contribute ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and ...

Analysts' ratings for Madrigal Pharmaceuticals (NASDAQ:MDGL) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below offers a condensed view of their recent ...

Sept 10 (Reuters) - LB Pharmaceuticals raised $285 million in its U.S. initial public offering, the biotech firm said on Wednesday, marking the first sizable biotech IPO since February. The New ...

The Trump administration is targeting "misleading drug advertisements" by initiating rule making to close a 1997 loophole that enables drug advertisers to conceal safety risks in broadcast and digital ...

President Donald Trump signed an executive order modifying the scope of tariffs for certain imports, including pharmaceuticals, yet some of the proposed changes are dependent on the U.S. reaching ...

CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...